Illumina, Inc. 2015 Q1 Form 10-Q Summary
Business Context and Reporting Period
Illumina is a global provider of sequencing- and array-based systems, consumables, services, and informatics solutions for genetic analysis. Customers include research institutions, hospitals, laboratories, pharmaceutical and biotechnology companies, and consumer genomics businesses.
The filing covers the 13-week quarter ended March 29, 2015, compared with the 13-week quarter ended March 30, 2014. The financial statements are unaudited and prepared under U.S. GAAP.
Key Financial Metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Total revenue | $538.6 million | $420.8 million | +28% |
| Product revenue | $459.1 million | $362.2 million | +27% |
| Service and other revenue | $79.4 million | $58.6 million | +36% |
| Gross profit | $375.0 million | $278.3 million | +35% |
| Gross margin | 69.6% | 66.1% | +350 basis points |
| Income from operations | $176.1 million | $92.1 million | +91% |
| Operating margin | 32.7% | 21.9% | +1,080 basis points |
| Net income | $136.7 million | $60.0 million | +128% |
| Net margin | 25.4% | 14.3% | +1,110 basis points |
| Diluted EPS | $0.92 | $0.40 | +$0.52 |
| Cash flow from operations | $66.8 million | $37.1 million | +80% |
Consumables revenue increased 27% to $308.4 million, driven primarily by growth in sequencing consumables and the installed instrument base. Instrument revenue increased 26% to $146.4 million, primarily from high-throughput sequencing platforms. Service and other revenue benefited from higher sequencing service volumes, growth in noninvasive prenatal testing services, and expanded instrument service contracts.
Management stated that revenue would have increased 33% on a constant-currency basis, compared with the reported 28% increase.
Financial Position, Debt, and Liquidity
- Cash and cash equivalents were $533.5 million at March 29, 2015, down from $636.2 million at December 28, 2014.
- Short-term investments were $833.0 million, bringing cash, cash equivalents, and short-term investments to approximately $1.4 billion.
- Total assets were $3.50 billion and stockholders’ equity was $1.62 billion.
- Convertible debt had $1.470 billion of principal outstanding and a $1.301 billion net carrying value, including $307.4 million classified as current debt.
- The debt consisted of $320.0 million of 0.25% convertible notes due March 2016, $632.5 million of zero-coupon convertible notes due June 2019, and $517.5 million of 0.5% convertible notes due June 2021.
- The 2016 notes remained convertible through June 30, 2015 because a stock-price conversion condition was met. The 2019 and 2021 notes were not convertible as of March 29, 2015.
- Management expects existing cash, investments, and operating cash flow to fund near-term operating and capital requirements for at least the next 12 months.
Material Changes Versus the Prior Comparable Period
- Revenue growth was broad-based, with particularly strong sequencing consumables, high-throughput instruments, sequencing services, and NIPT services.
- Gross margin improved due partly to higher-margin sequencing instrument sales and the absence of legal contingency charges associated with Syntrix patent litigation recorded in Q1 2014.
- Research and development expense increased 19% to $91.8 million, primarily from increased headcount and product-development investment.
- Selling, general and administrative expense increased 6% to $116.3 million as the Company expanded headcount, outside services, and operating infrastructure.
- Operating results benefited from a $9.9 million acquisition-related gain from a reduction in the fair value of contingent consideration, compared with a $1.0 million gain in Q1 2014.
- Other income included a $12.6 million net gain related primarily to the sale of a cost-method investment. The filing separately states that the investment sale generated a $15.1 million gain.
- The effective tax rate declined to 23.2% from 28.4%, aided by lower-tax foreign earnings, reversal of a valuation allowance related to research and development credits, and tax deductions related to stock awards.
- Operating cash flow increased to $66.8 million, but cash declined because of $154.1 million of investing outflows and $12.5 million of financing outflows.
- Capital expenditures increased to $36.6 million from $19.0 million, primarily for facilities, information technology, manufacturing, and research and development equipment.
- Share repurchases declined to $34.8 million from $130.0 million. Approximately $95.6 million remained authorized for repurchases at quarter-end.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide specific full-year revenue, earnings, or margin guidance. Management expects continued demand for sequencing technologies and consumables as the installed base expands. Management also expects array demand from consumer, reproductive health, and applied markets to offset some migration of array studies to sequencing.
Management expects research and development and selling, general and administrative expenses to continue increasing. Future gross margin will depend on pricing, sales and product mix, manufacturing costs, royalties, and the success of new products. The Company expects its effective tax rate to remain below the U.S. federal statutory rate because of earnings in lower-tax jurisdictions, although the rate may fluctuate.
- Competition, technological change, pricing pressure, manufacturing execution, and the ability to develop and commercialize new products could affect results.
- Foreign exchange movements affected reported revenue and remain a risk; the Company had foreign exchange forward contracts with aggregate notional amounts of $69.9 million at quarter-end.
- The Company is exposed to debt-conversion and potential early-repayment obligations, including the $320.0 million of 2016 convertible notes.
- Pending litigation and intellectual-property matters remain inherently uncertain. The Company cannot meaningfully estimate the potential loss or range of loss for certain matters.
- The IRS was examining tax year 2011, although no adjustments had been proposed as of the filing.
- The Company entered into new facility lease arrangements with estimated minimum payments of $204.0 million over 16 years, plus an additional $44.1 million over 15 years under a headquarters lease amendment involving a board member’s other board affiliation.
- ASU 2015-02 is effective for the Company in the first quarter of 2016, and ASU 2014-09 is effective in the first quarter of 2017. The Company was evaluating their impact.
Important Facts for Investors to Verify
- Whether sequencing consumables and instrument growth continues to support the reported revenue trajectory.
- Whether the 69.6% gross margin is sustainable after excluding the favorable comparison from prior-period legal charges and considering product mix.
- The timing and settlement economics of the $320.0 million 2016 convertible notes and potential dilution from convertible debt and equity awards.
- Whether operating cash flow improves relative to net income, given working-capital uses from receivables and inventory.
- The recurrence of the $12.6 million cost-method investment gain and the $9.9 million acquisition-related gain.
- Future effective tax rates, including the extent to which discrete tax benefits and foreign earnings affect reported results.
- Potential outcomes and accruals related to litigation, intellectual-property disputes, tax examinations, contingent consideration, and facility commitments.